IPP Bureau
AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024
By IPP Bureau - September 05, 2024
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets USP, 200 mg
By IPP Bureau - September 05, 2024
Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head
By IPP Bureau - September 05, 2024
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Apollo Hospitals launches Apollo Research Academy
By IPP Bureau - September 05, 2024
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India
By IPP Bureau - September 05, 2024
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
By IPP Bureau - September 05, 2024
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Alkem signs license agreement with Takeda to commercialise Vonoprazan in India
By IPP Bureau - September 04, 2024
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Enzene appoints new site lead of biologics manufacturing
By IPP Bureau - September 04, 2024
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
AstraZeneca advances ambition to improve standards of care in multiple cancer types
By IPP Bureau - September 04, 2024
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
By IPP Bureau - September 04, 2024
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
By IPP Bureau - September 04, 2024
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
STEER World appoints Dhiraj Tiwari as CFO
By IPP Bureau - September 04, 2024
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
Siegfried opens quality control lab in Minden
By IPP Bureau - September 04, 2024
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
By IPP Bureau - September 04, 2024
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Lupin launches Mirabegron ER tablets in US
By IPP Bureau - September 04, 2024
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
